Mutations of the BRAF gene in human cancer
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis signalling pathways in which at least one gene is mutated in human cancer. The RAS RAF MEK ERK MAP kinase pathway mediates cellular responses to growth signals. RAS is mutated to an oncogenic form in about 15% of human cancer. The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS. Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers. All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%. Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells. Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation. As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The hotspot BRAF V600E mutation at codon 600 of exon 15 increases the activity of BRAF kinase by 130- to 700-fold [26, 93–95].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [95]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations occur in ∼10% of colorectal cancer (CRC) patients, leading to poor prognosis.”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations are present in around 10% of advanced CRC patients and lead to constitutive activation of the MAPK pathway, drug resistance and a poor prognosis [1–4].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF mutations occur in roughly 5–15% of CRCs (1–3, 17)”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [17]
In the citing paper
“Among patients with colorectal cancer, there is an approximately 10% incidence of BRAF mutation [36].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [36]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“There has recently been marked success reported of an inhibitor (STI571) of the BCR-ABL kinase in the treatment of chronic myeloid leukaemi”
BackgroundIdentification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015 · cited 1×
“To evaluate whether activating mutations of BRAF signal through MEK and ERK, we treated cells with the MEK1/2 inhibitor U0126 (ref”
MethodMeaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
BackgroundRequirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells
Mulcahy, L. S., Smith, M. R., & Stacey, D. W. (1985) · Nature · doi:10.1038/313241a0 · Cited by 878 · cited 1×
“Studies using injection of the RAS-neutralizing Y13-259 monoclonal antibody have previously shown that most normal cells examined and some tumour cells require RAS function for proliferation in cultur”
MethodThe Raf/MEK/ERK pathway: new concepts of activation
Peyssonnaux, C., & Eychène, A. (2001) · Biology of the Cell · doi:10.1016/s0248-4900(01)01125-x · Cited by 735 · cited 1×
“The RAS–RAF–MEK–ERK–MAP kinase pathway mediates cellular responses to growth signal”
BackgroundIncreasing Complexity of the Ras Signaling Pathway
Vojtek, A. B., & Der, C. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.19925 · Cited by 579
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
Mason, C. S. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2137 · Cited by 457 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationRas Activation of the Raf Kinase: Tyrosine Kinase Recruitment of the MAP Kinase Cascade
Avruch, J. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.127 · Cited by 391 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
Background
Cited by
Items 601–700 of 1,144
14-3-3 Proteins—a focus on cancer and human disease
Wilker, E., & Yaffe, M. B. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.04.015 · Cited by 252
TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma
Griewank, K. G., Murali, R., Puig-Butille, J. A., Schilling, B., Livingstone, E., Potrony, M., Carrera, C., Schimming, T., Möller, I., Schwamborn, M., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju246 · Cited by 254
“Sex Female 170 (47) Male 192 (53) Age, y Median 58 Range 16–94 ≤60 179 (49) >60 173 (48) Missing data 10 (3) Mutant oncogene BRAF 128 (36) NRAS 68 (19) KIT 2 (1) TERT promoter mutations† All mutations 154/362 (43%) 250C>T 77 (50) 228C>T 47 (31) 242CC>TT 20 (13) 228CC>TT 10 (6) 228C>T 230C>T 2 (1) 228C>T 242C>T 1 (1) 2…”
BackgroundMelanocytic nevi and melanoma: unraveling a complex relationship
Damsky, W. E., & Bosenberg, M. (2017) · Oncogene · doi:10.1038/onc.2017.189 · Cited by 248
Fecher, L. A., Amaravadi, R. K., & Flaherty, K. T. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f5271c · Cited by 249
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
Davies, M. A., Stemke-Hale, K., Lin, E., Tellez, C., Deng, W., Gopal, Y. N., Woodman, S. E., Calderone, T. C., Ju, Z., Lazar, A. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1985 · Cited by 252
“These mutations result in constitutive activation of BRAF, with resultant activation of MAPK in vitro (4).”
BackgroundDivergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells
Lim, K.-H., O'Hayer, K., Adam, S. J., Kendall, S. D., Campbell, P. M., Der, C. J., & Counter, C. M. (2006) · Current Biology · doi:10.1016/j.cub.2006.10.023 · Cited by 250
“Studies of Ras transformation in experimental rodentmodel cell systems, together with the identification of mutationally activated and transforming alleles of BRaf [5] and the p110a subunit of PI3K [9], have argued that the Raf-MEK-ERK and PI3K-Akt effector pathways are the most crucial signaling mechanisms for Ras-me…”
BackgroundOgino, S., Brahmandam, M., Cantor, M., Namgyal, C., Kawasaki, T., Kirkner, G., Meyerhardt, J. A., Loda, M., & Fuchs, C. S. (2006) · Modern Pathology · doi:10.1038/modpathol.3800482 · Cited by 252
“Activating mutation of the BRAF gene is common in malignant melanoma, but less frequent in colorectal carcinoma”
The WNT/Beta-catenin pathway in melanoma
Larue, L. (2006) · Frontiers in Bioscience · doi:10.2741/1831 · Cited by 250
“Mutations have been described in genes encoding proteins involved in the MAP-kinase and Wnt/beta-catenin signaling pathways and in genes encoding cell cycle regulators, such as Ink4a, Arf and CDK4 (1-5) .”
BackgroundXing, M., Tufano, R. P., Tufaro, A. P., Basaria, S., Ewertz, M., Rosenbaum, E., Byrne, P. J., Wang, J., Sidransky, D., & Ladenson, P. W. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032050 · Cited by 251
“BRAF gene mutations are common in human cancers (10).”
BackgroundMethodInfluentialIhle, M. A., Fassunke, J., König, K., Grünewald, I., Schlaak, M., Kreuzberg, N., Tietze, L., Schildhaus, H.-U., Büttner, R., & Merkelbach-Bruse, S. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-13 · Cited by 246
“BRAF mutations play an important role in 40 – 70% of malignant melanomas, 45% of papillary thyroid cancers and 10% of colorectal cancers besides ovarian, breast and lung cancers [2-4].”
BackgroundMutant BRAF Melanomas—Dependence and Resistance
Poulikakos, P. I., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.008 · Cited by 250
McDermott, D. F., Sosman, J. A., Gonzalez, R., Hodi, F. S., Linette, G. P., Richards, J., Jakub, J. W., Beeram, M., Tarantolo, S., Agarwala, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8288 · Cited by 250
Molecular Biology of Lung Cancer: Clinical Implications
Larsen, J. E., & Minna, J. D. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.08.003 · Cited by 245
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
da Rocha Dias, S., Friedlos, F., Light, Y., Springer, C., Workman, P., & Marais, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2632 · Cited by 246
“Next, we examined endogenous proteins in melanoma cell lines, using a line in which B-RAF is wild type (CHL cells) and another that carries a B-RAF mutation (A375 cells) for comparison (11).”
BackgroundSelf-citationMolecular Markers and Targets in Melanoma
Teixido, C., Castillo, P., Martinez-Vila, C., Arance, A., & Alos, L. (2021) · Cells · doi:10.3390/cells10092320 · Cited by 219
“Mutated BRAFV600 leads to elevated BRAF kinase activity and sustained activation of downstream targets, in addition to unresponsive negative feedback mechanisms [20].”
BackgroundInfluentialK-ras as a target for cancer therapy
Friday, B. B., & Adjei, A. A. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.08.001 · Cited by 241
Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
Levy, J. M. M., Thompson, J. C., Griesinger, A. M., Amani, V., Donson, A. M., Birks, D. K., Morgan, M. J., Mirsky, D. M., Handler, M. H., Foreman, N. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0049 · Cited by 246
Molecular pathology of lung cancer: key to personalized medicine
Cheng, L., Alexander, R. E., MacLennan, G. T., Cummings, O. W., Montironi, R., Lopez-Beltran, A., Cramer, H. M., Davidson, D. D., & Zhang, S. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.215 · Cited by 246
“118 Mutant BRAF proteins have elevated kinase activity and can transform NIH3T3 cells”
BackgroundSanmamed, M. F., Fernández-Landázuri, S., Rodríguez, C., Zárate, R., Lozano, M. D., Zubiri, L., Perez-Gracia, J. L., Martín-Algarra, S., & González, A. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.230235 · Cited by 243
Heat Shock Protein 90 as a Drug Target: Some Like It Hot
Banerji, U. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0132 · Cited by 244
Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
Ellerhorst, J. A., Greene, V. R., Ekmekcioglu, S., Warneke, C. L., Johnson, M. M., Cooke, C. P., Wang, L.-E., Prieto, V. G., Gershenwald, J. E., Wei, Q., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2276 · Cited by 243
RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis
Ciampi, R., & Nikiforov, Y. E. (2007) · Endocrinology · doi:10.1210/en.2006-0921 · Cited by 241
Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
Ahmad, T., & Eisen, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040028 · Cited by 244
“Although the compound was initially designed as a RAF inhibitor (CRAF and BRAF), preliminary studies to date have not demonstrated BRAF mutations in renal cell carcinoma (14) unlike in malignant melanoma, which has been found to exhibit BRAF mutations in 70% of cases (15).”
BackgroundFrom basic research to clinical development of MEK1/2 inhibitors for cancer therapy
Frémin, C., & Meloche, S. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-8 · Cited by 243
“More recently, large-scale resequencing studies have revealed that BRAF is mutated in ~20% of all cancers and in more than 40% of melanomas [57].”
BackgroundHoeflich, K. P., Merchant, M., Orr, C., Chan, J., Den Otter, D., Berry, L., Kasman, I., Koeppen, H., Rice, K., Yang, N.-Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1515 · Cited by 242
“Activating BRAFmutations, the majority of which are a single amino acid substitution (V600E) in the activation loop of the kinase (6, 7), are prevalent in malignant melanomas (66%) and are also found in colon cancer (15%) and thyroid papillary carcinoma (27%).”
BackgroundIntracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy
Adjei, A. A., & Hidalgo, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.648 · Cited by 238
BRAF and NRAS mutations in melanoma and melanocytic nevi
Poynter, J. N., Elder, J. T., Fullen, D. R., Nair, R. P., Soengas, M. S., Johnson, T. M., Redman, B., Thomas, N. E., & Gruber, S. B. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000222600.73179.f3 · Cited by 245
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Abel, E. V., Basile, K. J., Kugel, C. H., Witkiewicz, A. K., Le, K., Amaravadi, R. K., Karakousis, G. C., Xu, X., Xu, W., Schuchter, L. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65780 · Cited by 244
“These include increased growth factor signaling (1), activating mutations in NRAS and KRAS (2), and, most prevalently, activating mutations in the serine/threonine kinase BRAF (3).”
Haling, J. R., Sudhamsu, J., Yen, I., Sideris, S., Sandoval, W., Phung, W., Bravo, B. J., Giannetti, A. M., Peck, A., Masselot, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.007 · Cited by 252
“For example, the kinase activating BRAFV600E mutation, found in more than 60% of melanomas, promotes MAPK pathway signaling independent of RAS activation (Davies et al., 2002; Wan et al., 2004).”
BackgroundRahmani, M., Davis, E. M., Crabtree, T. R., Habibi, J. R., Nguyen, T. K., Dent, P., & Grant, S. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01080-06 · Cited by 241
“MEK1/2-ERK1/2 module occurs in a high percentage (30%) of human cancers ( 12 , 42, 48, 57) provided a rationale for attempting to disrupt this pathway as a candidate anticancer strategy.”
BackgroundHoon, D. S. B., Spugnardi, M., Kuo, C., Huang, S. K., Morton, D. L., & Taback, B. (2004) · Oncogene · doi:10.1038/sj.onc.1207505 · Cited by 241
Haass, N. K., Sproesser, K., Nguyen, T. K., Contractor, R., Medina, C. A., Nathanson, K. L., Herlyn, M., & Smalley, K. S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1440 · Cited by 244
Sheen, J.-H., Zoncu, R., Kim, D., & Sabatini, D. M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.012 · Cited by 239
“Therefore, we asked if expression of oncogenic BRAF-V600E, the most common BRAF mutant allele found in melanoma (Davies et al., 2002), mimics the effects of RAS-G12V and MEK1-Q56P in sensitizing melanocytes to apoptosis upon leucine deprivation.”
BackgroundOcular melanoma: an overview of the current status.
Jovanovic, P., Mihajlović, M., Djordjević-Jocić, J., Vlajkoviç, S., Cekić, S., & Stefanović, V. (2013) · Europe PMC (PubMed Central) · Cited by 240
Protein kinase signaling networks in cancer
Brognard, J., & Hunter, T. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.012 · Cited by 240
“Successful targeting of mutant B-RAF Mutations in B-RAF (particularly V600E) have conclusively been characterized as driver mutations that promote the constitutive activation of the MEK1/2–ERK1/2 signaling pathway, which activates transcription to drive cellular proliferation [49].”
Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research
Gazdar, A. F., Girard, L., Lockwood, W. W., Lam, W. L., & Minna, J. D. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq279 · Cited by 239
Mabray, M. C., Barajas, R. F., & Cha, S. (2015) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2015.3.1.8 · Cited by 237
“Activating BRAF mutations are seen in numerous malignancies, most frequently however in melanoma [49].”
BackgroundRoberts, P. J., Stinchcombe, T. E., Der, C. J., & Socinski, M. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4365 · Cited by 240
Lurquin, C., Lethé, B., De Plaen, E., Corbière, V., Théate, I., van Baren, N., Coulie, P. G., & Boon, T. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041378 · Cited by 240
“The melanoma of patient EB81 carries the BRAF-1 mutation, which is present in most melanomas (4).”
BackgroundMethodInfluentialAtezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Sullivan, R. J., Hamid, O., Gonzalez, R., Infante, J. R., Patel, M. R., Hodi, F. S., Lewis, K. D., Tawbi, H. A., Hernandez, G., Wongchenko, M. J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0474-7 · Cited by 238
Phipps, A. I., Buchanan, D. D., Makar, K. W., Win, A. K., Baron, J. A., Lindor, N. M., Potter, J. D., & Newcomb, P. A. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.118 · Cited by 238
How I treat Langerhans cell histiocytosis
Allen, C. E., Ladisch, S., & McClain, K. L. (2015) · Blood · doi:10.1182/blood-2014-12-569301 · Cited by 233
Castro, P., Rebocho, A. P., Soares, R. J., Magalhães, J., Roque, L., Trovisco, V., Vieira de Castro, I., Cardoso-de-Oliveira, M., Fonseca, E., Soares, P., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1336 · Cited by 240
Su, X., Shen, Z., Yang, Q., Sui, F., Pu, J., Ma, J., Ma, S., Yao, D., Ji, M., & Hou, P. (2019) · Theranostics · doi:10.7150/thno.35219 · Cited by 238
“It is well known that BRAF mutation is the most common genetic alteration in thyroid cancer [11,33].”
BackgroundPrecision oncology in metastatic colorectal cancer — from biology to medicine
Di Nicolantonio, F., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 239
Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., Eisenberg, P. D., Selaru, P., Wilner, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1920 · Cited by 237
“Confusional state 3 (23) 1 (8) 0 3 (14) 1 (5) 0”
BackgroundInfluentialMalignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”
Pflugfelder, A., Kochs, C., Blum, A., Capellaro, M., Czeschik, C., Dettenborn, T., Dill, D., Dippel, E., Eigentler, T., Feyer, P., et al. (2013) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.12113_suppl · Cited by 239
Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
Callahan, M. K., Rampal, R., Harding, J. J., Klimek, V. M., Chung, Y. R., Merghoub, T., Wolchok, J. D., Solit, D. B., Rosen, N., Abdel-Wahab, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208958 · Cited by 240
MicroRNA Expression Profiles Associated with Mutational Status and Survival in Malignant Melanoma
Caramuta, S., Egyházi, S., Rodolfo, M., Witten, D., Hansson, J., Larsson, C., & Lui, W.-O. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.63 · Cited by 237
“Activating BRAF mutations, which affect the mitogenactivated protein kinase (MAPK) pathway, are detected in 50–70% of melanomas (Davies et al., 2002).”
BackgroundIn ovarian neoplasms, BRAF , but not KRAS , mutations are restricted to low‐grade serous tumours
Sieben, N. L., Macropoulos, P., Roemen, G. M., Kolkman‐Uljee, S. M., Jan Fleuren, G., Houmadi, R., Diss, T., Warren, B., Al Adnani, M., de Goeij, A. P., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1521 · Cited by 237
“In contrast, Davies et al [1] reported that BRAF mutations in the ovary are largely associated with SBTs, and not with high-grade SCAs.”
BackgroundResultSelf-citationKey Roles for Transforming Growth Factor β in Melanocyte Stem Cell Maintenance
Nishimura, E. K., Suzuki, M., Igras, V., Du, J., Lonning, S., Miyachi, Y., Roes, J., Beermann, F., & Fisher, D. E. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2009.12.010 · Cited by 235
“Melanoma cells, most of which exhibit constitutively active MAPK because of B-raf (Davies et al., 2002), N-ras (van ’t Veer et al., 1989), or Kit (Chin et al., 2006; Curtin et al., 2006) mutations, were resistant to TGF-b treatment (Figure S3B).”
The human genome and drug discovery after a decade. Roads (still) not taken
Isserlin, R., Bader, G. D., Edwards, A. M., Frye, S. V., Willson, T. M., & Yu, F. H. (2011) · arXiv (Cornell University) · doi:10.48550/arxiv.1102.0448 · Cited by 232
Clinical development of targeted and immune based anti-cancer therapies
Seebacher, N. A., Stacy, A. E., Porter, G. M., & Merlot, A. M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1094-2 · Cited by 231
Barnhill, R. L. (2006) · Modern Pathology · doi:10.1038/modpathol.3800519 · Cited by 235
“48 The general absence of B- raf mutations in Spitzoid lesions contrasts with a high rate of mutation (53–80p) in conventional melanoma”
BackgroundFugazzola, L., Puxeddu, E., Avenia, N., Romei, C., Cirello, V, Cavaliere, A., Faviana, P., Mannavola, D., Moretti, S., Rossi, S., et al. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01086 · Cited by 237
“%) and, with a lower prevalence (10–20%), also in colon and ovarian cancer, in lung and stomach cancer and in sarcomas (Davies et al. 2002).”
Nikiforov, Y. E. (2004) · Endocrine Pathology · doi:10.1385/ep:15:4:319 · Cited by 234
BRAF Mutation Status in Gastrointestinal Stromal Tumors
Hostein, I., Faur, N., Primois, C., Boury, F., Denard, J., Emile, J.-F., Bringuier, P.-P., Scoazec, J.-Y., & Coindre, J.-M. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcppckga2qgbj1r · Cited by 232
Targeting the BRAF V600E Mutation in Multiple Myeloma
Andrulis, M., Lehners, N., Capper, D., Penzel, R., Heining, C., Huellein, J., Zenz, T., von Deimling, A., Schirmacher, P., Ho, A. D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0014 · Cited by 234
Asl, E. R., Amini, M., Najafi, S., Mansoori, B., Mokhtarzadeh, A., Mohammadi, A., Lotfinejad, P., Bagheri, M., Shirjang, S., Lotfi, Z., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119499 · Cited by 231
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) Mutations in Distinct Subsets of Pancreatic Cancer
Calhoun, E. S., Jones, J. B., Ashfaq, R., Adsay, V., Baker, S. J., Valentine, V., Hempen, P. M., Hilgers, W., Yeo, C. J., Hruban, R. H., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63485-2 · Cited by 232
“Two xenografted pancreatic tumors and the COLO357 cell line were each found to harbor the BRAF codon V599E mutation (Figure 1; Table 1) previously shown to stimulate the kinase activity of Braf.19 Sequencing of BRAF in the two available constitutional DNA samples from these patients, as well as in an additional 74 typ…”
BackgroundReversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
Atefi, M., von Euw, E., Attar, N., Ng, C., Chu, C., Guo, D., Nazarian, R., Chmielowski, B., Glaspy, J. A., Comin-Anduix, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028973 · Cited by 227
“BRAF is a dominant activating mutation in melanoma resulting in a constitutive activation of the mitogen-activated protein kinase (MAPK) pathway and uncontrolled cell growth [1,2].”
BackgroundFurney, S. J., Turajlic, S., Stamp, G., Nohadani, M., Carlisle, A., Thomas, J. M., Hayes, A., Strauss, D., Gore, M., van den Oord, J., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4204 · Cited by 229
Self-citationFailure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment
Gajewski, T. F. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0892 · Cited by 230
Shukla, N., Ameur, N., Yilmaz, I., Nafa, K., Lau, C.-Y., Marchetti, A., Borsu, L., Barr, F. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2056 · Cited by 232
“A BRAF mutation has been previously identified in the Ewing sarcoma cell line A673 as well as in 2 RMS cell lines not used in our study (1).”
Kimple, A. J., Bosch, D. E., Giguère, P. M., & Siderovski, D. P. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003038 · Cited by 230
“…proliferative signaling through the extracellular signalregulated kinase/mitogen-activated protein kinase signaling cascade in a manner similar to that of the activating mutations to B-Raf that are observed with high frequency in cutaneous melanoma [e.g., B-Raf(V600E) (Davies et al., 2002)].”
BackgroundStructural features of the protein kinase domain and targeted binding by small-molecule inhibitors
Arter, C., Trask, L., Ward, S., Yeoh, S., & Bayliss, R. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102247 · Cited by 218
Recurrent KRAS codon 146 mutations in human colorectal cancer
Edkins, S., & O’Meara, S. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.8.3251 · Cited by 229
Self-citationTargeting tumour-supportive cellular machineries in anticancer drug development
Dobbelstein, M., & Moll, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 229
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Barras, D., Missiaglia, E., Wirapati, P., Sieber, O. M., Jorissen, R. N., Love, C., Molloy, P. L., Jones, I. T., McLaughlin, S., Gibbs, P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0140 · Cited by 230
“The BRAF gene is activated by mutation in 50% of melanomas and 10% of colorectal cancer (2).”
BackgroundInfluentialPanCancer insights from The Cancer Genome Atlas: the pathologist's perspective
Cooper, L. A., Demicco, E. G., Saltz, J. H., Powell, R. T., Rao, A., & Lazar, A. J. (2018) · The Journal of Pathology · doi:10.1002/path.5028 · Cited by 228
The multifaceted role of autophagy in cancer
Russell, R. C., & Guan, K. (2022) · The EMBO Journal · doi:10.15252/embj.2021110031 · Cited by 222
“In addition to KRAS , mutations in the kinase domain of Braf are found in ~ 3% of lung cancer (Davies et al , 2002).”
Lrrk2 pathogenic substitutions in Parkinson's disease
Mata, I. F., Kachergus, J. M., Taylor, J. P., Lincoln, S., Aasly, J., Lynch, T., Hulihan, M. M., Cobb, S. A., Wu, R.-M., Lu, C.-S., et al. (2005) · Neurogenetics · doi:10.1007/s10048-005-0005-1 · Cited by 231
“Of interest, substitutions within the activation segment of other kinases have an activating and oncogenic effect [22].”
BackgroundSomatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas
Lee, J. W., Soung, Y. H., Seo, S. H., Kim, S. Y., Park, C. H., Wang, Y. P., Park, K., Nam, S. W., Park, W. S., Kim, S. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0976 · Cited by 228
Clinical Implications of the Cancer Genome
MacConaill, L. E., & Garraway, L. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4944 · Cited by 229
“One of the first pivotal discoveries to emerge from systematic tumor sequencing was that of activating mutations within BRAF, which encodes a serine/threonine kinase oncogene that transmits proliferative and survival signals downstream of RAS in the mitogen-activated protein (MAP) kinase cascade.(17) BRAF mutations (m…”
BackgroundThunnissen, E., Kerr, K. M., Herth, F. J. F., Lantuejoul, S., Papotti, M., Rintoul, R. C., Rossi, G., Skov, B. G., Weynand, B., Bubendorf, L., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.10.017 · Cited by 228
Vance, K. W., Carreira, S., Brosch, G., & Goding, C. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3045 · Cited by 230
“Importantly, no binding was detected when GST or a fragment of Tbx2 containing the T-box but lacking the transcriptional repression domain [GST-Tbx2(1-361)] was used in the pull-down assay with nuclear extract.”
BackgroundMethodOncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models
Hoeflich, K. P., Gray, D. C., Eby, M. T., Tien, J. Y., Wong, L., Bower, J., Gogineni, A., Zha, J., Cole, M. J., Stern, H. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2720 · Cited by 232
“Recently, activating somatic mutations in BRAF have been reported in 70% of melanomas (5, 13 ).”
BackgroundTargeting glutamine transport to suppress melanoma cell growth
Wang, Q., Beaumont, K. A., Otte, N. J., Font, J., Bailey, C. G., van Geldermalsen, M., Sharp, D. M., Tiffen, J. C., Ryan, R. M., Jormakka, M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28749 · Cited by 224
“Around 50% of melanoma patients have BRAF mutations,(44,45) with BRAF the most common mutation, leading to hyperactivation of the MAPK pathway.(44) The current therapy for melanoma is focused on inhibition of the MAPK signaling pathway.”
BackgroundGreaves, W. O., Verma, S., Patel, K. P., Davies, M. A., Barkoh, B. A., Galbincea, J. M., Yao, H., Lazar, A. J., Aldape, K. D., Medeiros, L. J., et al. (2013) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.10.002 · Cited by 227
Kumar, R., Angelini, S., Snellman, E., & Hemminki, K. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22225.x · Cited by 229
Soh, J., Okumura, N., Lockwood, W. W., Yamamoto, H., Shigematsu, H., Zhang, W., Chari, R., Shames, D. S., Tang, X., MacAulay, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007464 · Cited by 228
“After quantitation of each target and reference genes by the standard curve method, relative expression was calculated to compare the value of cell lines with the average value of HBEC 15 and 21 cell lines (for NSCLCs lines) or the value of human adult normal colon RNA (BioChain Institute, CA, USA) for CRC lines, resp…”
BackgroundInfluentialMetastatic Melanoma – A Review of Current and Future Treatment Options
Maverakis, E., Cornelius, L., Bowen, G., Phan, T., Patel, F., Fitzmaurice, S., He, Y., Burrall, B., Duong, C., Kloxin, A., et al. (2015) · Acta Dermato Venereologica · doi:10.2340/00015555-2035 · Cited by 224
“The BRAF gene encodes for a serine/threonine kinase that participates in the MAP kinase pathway (24).”
BackgroundWillmore-Payne, C., Holden, J. A., Tripp, S., & Layfield, L. J. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.03.015 · Cited by 230
“Activating mutations in the BRAF gene have been reported most commonly in exon 15, which codes for the activation loop of the kinase, and less so in exon 11, which codes for the glycine-rich conserved nucleotide binding site [17].”
BackgroundBRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF -Mutant Thyroid Cancer
Falchook, G. S., Millward, M., Hong, D., Naing, A., Piha-Paul, S., Waguespack, S. G., Cabanillas, M. E., Sherman, S. I., Ma, B., Curtis, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0123 · Cited by 227
“Constitutive activation of v-raf murine sarcoma viral oncogene homolog B (BRAF) by a somatic mutation results in oncogenic transformation of normal cells (5,6).”
BackgroundTie, J., Gibbs, P., Lipton, L., Christie, M., Jorissen, R. N., Burgess, A. W., Croxford, M., Jones, I., Langland, R., Kosmider, S., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25555 · Cited by 227
Gopal, Y. N. V., Deng, W., Woodman, S. E., Komurov, K., Ram, P., Smith, P. D., & Davies, M. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0902 · Cited by 229
MAPK pathway activation in pilocytic astrocytoma
Jones, D. T. W., Gronych, J., Lichter, P., Witt, O., & Pfister, S. M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0898-9 · Cited by 225
“Most often this is the hotspot valine to glutamate change at position 600 (V600E), first identified in 2002 and since then reported in a large number of tumor types ([77]; and see the Catalogue of Somatic Mutations in Cancer (COSMIC) at http://www.”
BackgroundSynthetic lethality between CCNE1 amplification and loss of BRCA1
Etemadmoghadam, D., Weir, B. A., Au-Yeung, G., Alsop, K., Mitchell, G., George, J., Australian Ovarian Cancer Study Group, Davis, S., D’Andrea, A. D., Simpson, K., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314302110 · Cited by 225
“Mutual exclusivity of oncogenic mutations in genes in the rat sarcoma viral oncogene homolog (RAS) signaling pathway, seen in low-grade serous ovarian cancer (21) and other solid cancers (22), seems to occur, because there is no selective advantage of compound mutations.”
BackgroundSøndergaard, J. N., Nazarian, R., Wang, Q., Guo, D., Hsueh, T., Mok, S., Sazegar, H., MacConaill, L. E., Barretina, J. G., Kehoe, S. M., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-39 · Cited by 228
“Discussion The BRAFV600E mutation is one of the most common kinase domain mutations in human cancer with a particularly high incidence in malignant melanoma [3,7].”
BackgroundMitsutake, N., Knauf, J. A., Mitsutake, S., Mesa, C., Zhang, L., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3314 · Cited by 228
“ERK phosphorylation and high transforming activity in NIH3T3 cells (1).”
BackgroundVan Cutsem, E., Huijberts, S., Grothey, A., Yaeger, R., Cuyle, P.-J., Elez, E., Fakih, M., Montagut, C., Peeters, M., Yoshino, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02459 · Cited by 224
“Median CEA at baseline, mg/mL (range) 28 (1-3,434)”
Both variant and IGHV4-34–expressing hairy cell leukemia lack the BRAF V600E mutation
Xi, L., Arons, E., Navarro, W., Calvo, K. R., Stetler-Stevenson, M., Raffeld, M., & Kreitman, R. J. (2012) · Blood · doi:10.1182/blood-2011-09-379339 · Cited by 225
Normal Human Melanocyte Homeostasis as a Paradigm for Understanding Melanoma
Haass, N. K., & Herlyn, M. (2005) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1111/j.1087-0024.2005.200407.x · Cited by 227
Safaee Ardekani, G., Jafarnejad, S. M., Tan, L., Saeedi, A., & Li, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047054 · Cited by 224
“BRAF mutation has become an important research topic in cancer biology since the original observation by Davies et al [3] in 2002.”
BackgroundDamsky, W. E., Rosenbaum, L. E., & Bosenberg, M. (2010) · Cancers · doi:10.3390/cancers3010126 · Cited by 225
“BRAF, a mitogenic Ser/Thr kinase in the MAPK/ERK pathway, has an activating mutation, V600E, in at least 50% of melanomas [218,219] and is thought to be a central oncogenic driver in melanoma.”
BackgroundTargeting the MAPK pathway in melanoma: Why some approaches succeed and other fail
Inamdar, G. S., Madhunapantula, S. V., & Robertson, G. P. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.029 · Cited by 225
“B-RAF is the most mutated gene in the MAPK signaling cascade in melanomas, with >60% of advanced tumors expressing constitutively active mutant protein [11,12,20].”
BackgroundReactivation of telomerase in cancer
Akincilar, S. C., Unal, B., & Tergaonkar, V. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2146-9 · Cited by 222
“observed in thyroid cancers [116].”
Mayr, D., Hirschmann, A., Löhrs, U., & Diebold, J. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.05.029 · Cited by 224
“The results of our study support, in agreement with data in the literature [23–25,13,14], the theory that a group of borderline tumors of serous and mucinous subtype might develop along the same pathways.”
ResultThyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice
Franco, A. T., Malaguarnera, R., Refetoff, S., Liao, X.-H., Lundsmith, E., Kimura, S., Pritchard, C., Marais, R., Davies, T. F., Weinstein, L. S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015557108 · Cited by 223
“Mutations of BRAF are also found with high frequency in benign nevi and in melanomas (12, 13) and to a lesser extent in lung cancers (14, 15).”
BackgroundSelf-citation
Metadata
- Authors
- Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W. C., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., & Futreal, P. A.
- Affiliations
- Wellcome Sanger Institute (GB)
- Institute of Cancer Research (GB)
- Western Infirmary (GB)
- University of York (GB)
- Duke University (US)
- National Research Council (IT)
- University of Sassari (IT)
- Royal Brompton Hospital (GB)
- Queen Mary Hospital (CN)
- Abramson Cancer Center (US)
- Corresponding author
- Wooster, Richard
- ORCID
- Davies, Helen
- Edkins, Sarah
- Teague, Jon
- Garnett, Mathew J.
- Dicks, Ed
- Gray, Kristian
- Hughes, Jaime
- Kosmidou, Vivian
- Menzies, Andrew
- Watt, Stephen
- Hooper, Steven
- Shipley, Janet
- Hargrave, Darren
- Maitland, Norman
- Riggins, Gregory J.
- Bigner, Darell D.
- Palmieri, Giuseppe
- Cossu, Antonio
- Flanagan, Adrienne
- Nicholson, Andrew
- Ho, Judy W. C.
- Yuen, Siu T.
- Paterson, Hugh
- Marais, Richard
- Stratton, Michael R.
- Futreal, P. Andrew
- Venue
- Nature
- Published
- 2002-06
- Volume
- 417
- Issue
- 6892
- Pages
- 949-954
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2163188200
- Cited by
- 10,674
- References
- 24
- Citations by year
- 2026: 221 · 2025: 282 · 2024: 435 · 2023: 450 · 2022: 442 · 2021: 506 · 2020: 538 · 2019: 482 · 2018: 519 · 2017: 576 · 2016: 576 · 2015: 649 · 2014: 701 · 2013: 688 · 2012: 563
- FWCI
- 87.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- BRAF mutation, somatic missense mutations, melanoma, oncogenic Ras, kinase activity, malignant transformation, therapeutic target
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Cell Division, Cell Transformation, Neoplastic, DNA Mutational Analysis, Enzyme Activation, Humans, Melanoma, Molecular Sequence Data, Neoplasms, Tumor Cells, Cultured, 3T3 Cells, Protein Structure, Tertiary, ras Proteins, Proto-Oncogene Proteins c-raf, Mutation, Missense, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, Proto-Oncogene Proteins B-raf, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.